More on GTBP

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/17/25 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

GT Biopharma (NQ:GTBP)
Delayed: 0.44 -0.04 (8.33%)
Prev. Close $0.48  
Open$0.47 
52 Wk High$ 
52 Wk Low$ 
Day High$0.47 
Day Low$0.43 
P/E N/A  
EPS$ 
Volume1,322,437 

Friends, Peers and Foes (?): LVG, LVGLF, VPT, VPTDF, CRBU (more...)

Jun 1, 2026 08:04 AM GT Biopharma integrates AI tools to accelerate drug discovery
Jun 1, 2026 08:00 AM GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
May 22, 2026 08:01 AM Form 8-K GT Biopharma, Inc. For: May 20
May 15, 2026 08:01 AM Form 10-Q GT Biopharma, Inc. For: Mar 31
May 15, 2026 08:00 AM GT Biopharma Reports First Quarter 2026 Financial Results
May 14, 2026 11:12 AM "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
May 14, 2026 10:55 AM "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
May 14, 2026 09:15 AM A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
May 14, 2026 08:30 AM GT Biopharma doses first patient in GTB-5550 solid tumor trial
May 14, 2026 08:30 AM GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
View All Articles

Entities mentioned with GTBP

View All Entities